Every day, thousands of patients enter clinical trials where a random process—like a computer flipping a coin—determines whether they receive a new treatment or a standard one. This randomisation is the gold standard for proving what works in medicine, but only if the trials themselves are designed, run, and analysed with rigorous statistical methods. The Hub in Trials Methodology Research at the MRC Biostatistics Unit in Cambridge will develop and promote those methods, working with existing clinical trial networks in areas such as cancer, dementia, arthritis, and primary care. The problem is that poorly designed trials waste time, money, and patient goodwill, and can produce misleading results that harm clinical decisions. This Hub will tackle statistical challenges in trial design, analysis, and interpretation—from early proof-of-concept studies to large pragmatic trials—and will also evaluate the cost-effectiveness of interventions to inform health policy. If successful, the Hub will make trials more efficient and informative, ensuring that new treatments—especially those leveraging imaging, genetics, or pharmacology—are identified and brought into practice faster, without compromising reliability. The impact is largely invisible to patients but fundamental: better data means better decisions for the NHS and for everyone who relies on it.
View original technical description
In clinical trials, the choice of which treatment a participant receives is decided by a random process. Such trials provide the foundation for deciding what medical interventions work, and in whom, and inform patient choice and clinical decision making. In order to be effective, however, trials must be well designed, well run, and well analysed and reported. The Hub in Trial Methodology Research based at the MRC Biostatistics Unit in Cambridge will develop and promote the use of efficient and state-of-the-art methods for trials. It will work with the existing extensive clinical trial research networks in Cambridge and East Anglia to support good practice in trials in specific clinical areas (for example in cancer, paediatrics, dementia, brain sciences, arthritis, and primary care). Trials will range from early proof-of-concept studies to large pragmatic trials of healthcare interventions. The proposed formation of the Hub has received an enthusiastic response from a large number of potential collaborators and networks in Cambridge and the local region. The Hub will also evaluate the cost-effectiveness of proposed interventions, to inform health policy decisions. In particular, it will investigate statistical problems involved in trial designs, and in the analysis and interpretation of the trial results. Methodological development and support are needed to improve study design, to run trials more efficiently, and to ensure that they are as informative as possible for both clinical and health policy decision making. Methodological development must also take advantage of new medical technologies (for example in imaging, in genetics, in pharmacology and drug targeting) so that new cost-effective treatments are identified efficiently and brought into medical practice.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know